BioXcel Therapeutics Raises $30.4M, Meets Financing Covenant

Bioxcel Therapeutics ( (BTAI) ) just unveiled an update.

BioXcel Therapeutics announced its CEO, Vimal Mehta, will participate in a fireside chat at the Canaccord Genuity 45th Annual Growth Conference on August 12, 2025. The company has successfully met its Oaktree Financing Covenant by raising approximately $30.4 million through various financings, including public offerings and an at-the-market program, as of August 8, 2025. This financial achievement strengthens BioXcel’s operational stability and supports its ongoing development efforts.

The most recent analyst rating on (BTAI) stock is a Buy with a $112.00 price target. To see the full list of analyst forecasts on Bioxcel Therapeutics stock, see the BTAI Stock Forecast page.

Spark’s Take on BTAI Stock

According to Spark, TipRanks’ AI Analyst, BTAI is a Underperform.

Bioxcel Therapeutics’ stock is rated at the lowest end of the scale due to substantial financial instability, including ongoing losses, high debt, and negative cash flows. Short-term technical indicators and valuation metrics further highlight the current challenges. The company needs to address these financial and operational issues to improve its stock performance.

To see Spark’s full report on BTAI stock, click here.

More about Bioxcel Therapeutics

BioXcel Therapeutics, Inc. is a biopharmaceutical company that leverages artificial intelligence to develop transformative medicines in neuroscience. The company, along with its subsidiary OnkosXcel Therapeutics, focuses on drug re-innovation by utilizing existing approved drugs and clinically validated product candidates, combined with big data and proprietary machine learning algorithms, to identify new therapeutic indications.

Average Trading Volume: 5,809,807

Technical Sentiment Signal: Sell

Current Market Cap: $24.47M

See more insights into BTAI stock on TipRanks’ Stock Analysis page.